Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 13/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30161668 | 1.00 | PDE4B (0.42) | PDE4BPIK3CDUSP30PIK3CAPIK3CB | |
| SCHEMBL20703727 | 0.89 | PDE4B (0.32) | PDE4B | |
| SCHEMBL20699347 | 0.89 | PDE4B (0.32) | PDE4B | |
| SCHEMBL20711762 | 0.85 | PDE4B (0.43) | PDE4BPIK3CDUSP30PIK3CAPIK3CB | |
| SCHEMBL28385243 | 0.85 | PDE4B (0.43) | PDE4BPIK3CDUSP30PIK3CAPIK3CB | |
| SCHEMBL29607485 | 0.85 | PDE4B (0.43) | PDE4BPIK3CDUSP30PIK3CAPIK3CB | |
| SCHEMBL29606524 | 0.84 | PIK3CD (0.41) | PDE4BPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL21796648 | 0.77 | PDE4B (0.43) | PDE4BPIK3CDPIK3CA | |
| SCHEMBL18398984 | 0.77 | PDE4B (0.43) | PDE4BPIK3CDPIK3CA | |
| SCHEMBL21796806 | 0.77 | PDE4B (0.43) | PDE4BPIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111032646-B | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | 施万生物制药研发IP有限责任公司 | 2023-01-03 | — | — | CN | disclosed |
| US-20220119369-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-04-21 | — | — | US | disclosed |
| CN-111032646-A | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | 施万生物制药研发IP有限责任公司 | 2020-04-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119369-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | JAK3, JAK1, JAK2 | PDE4B 1261/4885PIK3CD 207/4885USP30 2382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.